Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Ironwood Pharmaceuticals will pay about $1 billion to acquire Swiss biotech VectivBio and its lead drug apraglutide, betting that a weekly injection will take…
Ironwood Pharmaceuticals said Monday it would acquire VectivBio for roughly $1 billion, paying $17 a share for the Swiss-American rare disease biotech that is…
FDA will not approve apraglutide based on the original STARS Phase 3 trial alone; Ironwood must conduct a confirmatory Phase 3 study before NDA approval.…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
Ironwood entered a definitive agreement to acquire VectivBio for $17.00/share, total consideration ~$1B net of cash and debt, gaining apraglutide, a Phase 3 GLP-2 analog for SBS-IF positioned as a potential best-in-class follow-on to Linzess. Tender offer with HSR clearance.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Ironwood Pharmaceuticals, Inc. / VectivBio Holding AG (this deal) | 2023 | $1.0B | — |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Horizon Pharma plc / Hyperion Therapeutics, Inc. | 2015 | $1.1B | 79 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| AstraZeneca PLC / Amolyt Pharma | 2024 | $1.1B | 73 |
| Sanofi SA / Inhibrx Inc. | 2024 | $2.2B | 70 |
| Eli Lilly and Company / Hanmi Pharmaceutical Co. Ltd. | 2026 | $1.3B | 65 |
← Browse all deals · How we score deals
More: 2023 deals · Rare Disease deals